Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link?: What both cardiologist and oncologist should know about novel angiogenesis inhibitors

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2421-2429

  Conti, Elena ^a   Romiti, Adriana ^a   Musumeci, Maria Beatrice ^a   Passerini, Jasmine ^a   Zezza, Luigi ^a   Mastromarino, Vittoria ^a   D'Antonio, Chiara ^a   Marchetti, Paolo ^a   Paneni, Francesco ^b   Autore, Camillo ^a   Volpe, Massimo ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

Acute coronary syndromes; Angiogenesis inhibitors; Growth factors; IGF 1; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; ENOXAPARIN; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GEFITINIB; IMATINIB; LAPATINIB; MOTESANIB; NILOTINIB; PANITUMUMAB; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VATALANIB;

ACUTE CORONARY SYNDROME; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERY THROMBOSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; BREAST CANCER; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; COLON CANCER; COLORECTAL CANCER; CORONARY ARTERY THROMBOSIS; DEHYDRATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY CARCINOMA; LEUKOCYTOSIS; LIVER CELL CARCINOMA; LUNG CANCER; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; SOLID TUMOR; THROMBOSIS; VEIN THROMBOSIS;

ACUTE CORONARY SYNDROMES; ANGIOGENESIS INHIBITORS; GROWTH FACTORS; IGF-1; VEGF;

ACUTE CORONARY SYNDROME; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOLOGY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEDICAL ONCOLOGY; NEOPLASMS; PHYSICIAN'S ROLE; PLATELET AGGREGATION INHIBITORS;

EID: 84883803509     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.052     Document Type: Review

References (87)

1. E. Conti, M.B. Musumeci, and M. De Giusti IGF-1 and atherothrombosis: relevance to pathophysiology and therapy Clin Sci 120 2011 377 402
2. J. Passerini, A. Romiti, and C. D'Antonio Tailored angiogenesis inhibition in cancer therapy: respecting the heart to improve the net outcome Curr Signal Transduct Ther 24 2012 265 288
3. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
4. T.K. Choueiri, F.A. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
5. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
6. R.S. Kerbel, A. Viloria-Petit, G. Klement, and J. Rak "Accidental" anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples Eur J Cancer 36 2000 1248 1257
7. M.G. Slomiany, and S.A. Rosenzweig Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion J Pharmacol Exp Ther 318 2006 666 675
8. E. Pasquier, M. Kavallaris, and N. André Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 7 2010 455 465
9. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
10. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma (HCC) N Engl J Med 359 2008 378 390
11. V.L. Goodman, E.P. Rock, and R. Dagher Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma Clin Cancer Res 13 2007 1367 1373
12. S.V. Keisner, and S.R. Shah Pazopanib in the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma Drugs 71 2011 443 454
13. V.E. Kwitkowski, T.M. Prowell, and A. Ibrahim FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 15 2010 428 435
14. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
15. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2005 172 187
16. K. Imai, and A. Takaoka Comparing antibody and small-molecule therapies for cancer Nat Rev Cancer 6 2006 714 727
17. F. Wang, L.D. Wang, B. Li, and Z.X. Sheng Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials Clin Oncol (R Coll Radiol) 24 2012 396 401
18. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
19. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
20. R. Dematteo, M.C. Heinrich, W.M. El-Rifai, and G. Demetri Clinical management of gastrointestinal stromal tumours: before and after STI-571 Hum Pathol 33 2002 466 477
21. C.D. Blanke, G.D. Demetri, and M. von Mehren Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625
22. M.H. Chen, R. Kerkela, and T. Force Mechanism of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics Circulation 118 2008 84 95
23. K.J. Aichberger, S. Herndlhofer, and G.H. Schernthaner Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML Am J Hematol 86 2011 533 539
24. S. Ederhy, C. Massard, and G. Dufaitre Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials Invest New Drugs 2010 10.1007/s10637-010-9546-8
25. I.N. Daher, and E.T. Yeh Vascular complications of selected cancer therapies Nat Clin Pract Cardiovasc Med 5 2008 797 805
26. T.F. Chu, M.A. Rupnick, and R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
27. R. Kerkelä, L. Grazette, and R. Yacobi Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916
28. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
29. T. Doi, K. Muro, and N. Boku Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer J Clin Oncol 28 2010 1904 1910
30. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154
31. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
32. E.P. Rock, V. Goodman, and J.X. Jiang Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist 12 2007 107 113
33. V.R. Adams, and M. Leggas Sunitinib malate for the treatment of metastatic cell carcinoma and gastrointestinal stromal tumors Clin Ther 29 2007 1338 1353
34. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
35. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial Lancet 370 2007 2103 2111
36. B.C. Kuenen, L. Rosen, and E.F. Smit Dose finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 2002 1657 1667
37. A. Gualberto, and M. Pollak Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions Oncogene 28 2009 3009 3021
38. D.D. Karp, L.G. Paz-Ares, and S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
39. J. Jassem, C.J. Langer, and D.D. Karp Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer Best of ASCO San Francisco. Abstract 2010, 28;7500 Presented July 17 2010
40. C. Fernandez-Hernando, E. Ackah, and J. Yu Loss of Akt1leads to severe atherosclerosis and occlusive coronary artery disease Cell Metab 6 2007 446 457
41. C. Fernandez-Hernando, L. Jozsef, D. Jenkins, A. Di Lorenzo, and W.C. Sessa Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis Arterioscler Thromb Vasc Biol 29 2009 2033 2040
42. J. Rak Microparticles in cancer Semin Thromb Hemost 36 2010 888 906
43. H.A. Mostefai, R. Andriantsitohaina, and M.C. Martínez Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer Physiol Res 57 2008 311 320
44. F. Elice, F. Rodeghiero, A. Falanga, and F.R. Rickles Thrombosis associated with angiogenesis inhibitors Best Pract Res Clin Haematol 22 2009 115 128
45. R. Winn, and J. Harlan The role of endothelial cell apoptosis in inflammatory and immune diseases J Thromb Haemost 3 2005 1815 1824
46. D. Olmos, S. Postel-Vinay, and L.R. Molife Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study Lancet Oncol 11 2010 129 135
47. D.R. Lynch, T.S. Kickler, and J.J. Rade Recurrent myocardial infarction associated with gefitinib therapy J Thromb Thrombolysis 32 2011 120 124
48. H.M.W. Verheul, and H.M. Pinedo Possible molecular mechanism involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 2007 475 485
49. L.G. Lima, A.S. Oliveira, and L.C. Campos Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles Thromb Haemost 106 2011 712 723
50. O. Morel, B. Pereira, and G. Averous Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation Atherosclerosis 204 2009 636 641
51. T. Bombeli, A. Karsan, J.F. Tait, and J.M. Harlan Apoptotic vascular endothelial cells become procoagulant Blood 89 1997 2429 2442
52. C. Mold, and C.A. Morris Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation Immunology 102 2001 359 364
53. G.C. Connolly, A.A. Khorana, N.M. Kuderer, E. Culakova, C.W. Francis, and G.H. Lyman Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy Thromb Res 126 2010 113 118
54. L.L. Swystun, S. Mukherjee, and P.C. Liaw Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus J Thromb Haemost 9 2011 2313 2321
55. S. Sanon, D.J. Lenihan, and E. Mouhayar Peripheral arterial ischemic events in cancer patients Vasc Med 16 2011 119 130
56. P. Vihinen, O. Paija, A. Kivisaari, L. Koulu, and H. Aho Cutaneous lupus erythematosus after treatment with paclitaxel and bevacizumab for metastatic breast cancer: a case report J Med Case Reports 5 2011 243
57. E. Matsuura, and L.R. Lopez Autoimmune-mediated atherothrombosis Lupus 17 2008 878 887
58. A. Cederholm, and J. Frostegård Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population Ann N Y Acad Sci 1108 2007 96 103
59. D.S. Hong, S.M. Sebti, and R.A. Newman Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies Clin Cancer Res 15 2009 7061 7068
60. P. Haluska, F. Worden, and D. Olmos Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemother Pharmacol 65 2010 765 773
61. Y. Schechter, P. Yaish, M. Chorev, C. Gilon, S. Braun, and A. Levitzki Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors EMBO J 8 1989 1671 1676
62. O. Mir, L. Mouthon, and J. Alexandre Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 99 2007 85 86
63. D. Cardinale, A. Colombo, and G. Lamantia Anthracycline-induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
64. F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
65. N.C. Tebbutt, F. Murphy, and D. Zannino Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab Ann Oncol 22 2011 1834 1838
66. K.A. Eagle, M.J. Lim, and O.H. Dabbous A validated prediction model for all forms of acute coronary syndromes. Estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
67. C. Meune, B. Drexler, and P. Haaf The GRACE score's performance in predicting in-hospital and 1-year outcome in the era of high-sensitivity cardiac troponin assays and B-type natriuretic peptide Heart 97 2011 1479 1483
68. P.G. Morris, C. Chen, and R. Steingart Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib Clin Cancer Res 17 2011 3490 3499
69. Expert Working Group on Biomarkers of Drug-Induced Cardiac Toxicity report to the Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science http://www.fda.gov/ohrms/dockets/ac/02/briefing/ 3891B101Troponin 2002 [Outline.pdf NICE website press release]
70. D. Cardinale, M.T. Sandri, and A. Colombo Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
71. C. Heeschen, M.J. van Den Brand, C.W. Hamm, and M.L. Simoons Angiographic findings in patients with refractory unstable angina according to troponin T status Circulation 100 1999 1509 1514
72. C. Heeschen, C.W. Hamm, B. Goldmann, A. Deu, L. Langenbrink, and H.D. White Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management Lancet 354 1999 1757 1762
73. K.T. Papazisis, L.F. Kontovinis, and C.N. Papandreou Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma BMC Cancer 10 2010 489
74. M.T. Sandri, M. Salvatici, and D. Cardinale N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51 2005 1405 1410
75. D.J. Vaughn, S.C. Palmer, J.R. Carver, L.A. Lacobs, and E.R. Mohler Cardiovascular risk in long-term survivors of testicular cancer Cancer 112 2008 1949 1953
76. L.F. de Geus-Oei, A.M. Mavinkurve-Groothuis, and L. Bellersen Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity J Nucl Med 52 2011 560 571
77. A. Tzonevska, K. Tzvetkov, M. Atanasova, A. Chakarova, and E. Piperkova Myocardial scintigraphy, echocardiography and proBNP for early detection of myocardial cardiotoxicity in breast cancer patients after chemo-radiotherapy Hell J Nucl Med 14 2011 269 273
78. S. Verma, and M.S. Ewer Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 22 2011 1011 1018
79. H. Sawaya, I.A. Sebag, and J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
80. M.L. Telli, S.A. Hunt, R.W. Carlson, and A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533
81. F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thrombo-embolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239
82. M.G. Sarkiss, S.W. Yusuf, and C.L. Warneke Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes Cancer 109 2007 621 627
83. M. Cavo, E. Zamagni, and P. Tosi First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma Haematologica 89 2004 826 831
84. R. Baz, L. Li, and K. Kottke-Marchant The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma Mayo Clin Proc 80 2005 1568 1574
85. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
86. J.A. Overbeek, Z. Zhao, M.P. van Herk-Sukel, B.L. Barber, S. Gao, and R.M. Herings Costs of hospital events in patients with metastatic colorectal cancer J Med Econ 14 2011 656 661
87. A. Cheng, Y. Kang, and D. Lin Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) J Clin Oncol 29 2011 [Suppl.: abstr 4000]